Assessment Status | Rapid Review Complete |
HTA ID | 24007 |
Drug | Rezafungin |
Brand | Rezzayo® |
Indication | Rezafungin (Rezzayo®) is indicated for the treatment of invasive candidiasis in adults. |
Assessment Process | |
Rapid review commissioned | 22/03/2024 |
Rapid review completed | 26/03/2024 |
Rapid review outcome | A full HTA is not recommended. The NCPE recommends that rezafungin not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.